Urticaria

Panelists discuss how chronic spontaneous urticaria develops through 2 distinct pathways: autoallergic CSU involving IgE-mediated mast cell activation (type I hypersensitivity) and autoimmune CSU where IgG autoantibodies target FcεRI receptors or IgE itself (type IIb hypersensitivity), both ultimately leading to mast cell degranulation and wheal formation.

These findings were from a 52-week analysis of a Phase-2 trial in participants with chronic spontaneous urticaria.

Panelists discuss how chronic spontaneous urticaria involves autoantibody-mediated mast cell activation and degranulation, with BTK serving as a critical signaling molecule in both mast cells and B cells that produce pathogenic autoantibodies.

Dupilumab reduced itch and disease activity in patients with uncontrolled CSU, confirming prior findings from the LIBERTY-CUPID program in a phase 3 trial.

The latest indication for the dual inflammatory pathway-targeting biologic expands dupilumab's clinical availability to third chronic skin disease.

The biologic sustained responses in managing sleep interference with numerically higher responses than omalizumab.

Investigators noted that the epidemiology and disease overlap among eosinophilic diseases are poorly understood.

Investigators review the current understanding of the role of the BTK pathway and the potential value of pharmacological inhibition of BTK as a therapeutic strategy.

Dupilumab did not reach statistical significance in interim analysis despite numeric improvements being observed across key endpoints.

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

Investigators believe their study shows the efficacy and safety of the 2 biologic agents, which are known to have anti-inflammatory and immunosuppressant qualities.

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.

The approval of the sBLA means greater flexibility and reduced barriers in care during the pandemic.

The 5 companies issued letters will have 15 days to submit a compliance plan.

The FDA approvals of biologics for atopic dermatitis and psoriasis have ushered in a new era for the once-stagnant field of pediatric dermatology.

Approval allows Almirall to move forward with the topical ointment for individuals with AK on the face or scalp.

In new phase 3b findings, a greater proportion of patients treated with upadacitinib achieved EASI 75 at week 16 than those who received dupilumab.

There is a gap between the efficacy of biologics in trials and the real-world setting.

Strict avoidance of systemic corticosteroids among patients with psoriasis may be unnecessary.

Largest study of multiple health indicators over time finds widening disparities in health by race, despite increased targeted funding.

The risk of suicidality and psychological adverse events appears to be particularly high in younger men with alopecia who are given finasteride.

Newborns who were given a probiotic had lower rates of atopic dermatitis and lower symptom scores, according to a new study.

A new study confirms the link between chronic urticaria and fibromyalgia, though the correlation is not as strong as in a previous study.

The incidence or urticaria in patients does not depend on exposure to air pollution.

Drugs often trigger outbreaks of hives, but investigators observed no clear evidence as to the overall incidence of drug allergies in CSU.